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Abstract Since the development of technologies that can
determine the base-pair sequence of DNA, the ability to
sequence genes has contributed much to science and medi-
cine. However, it has remained a relatively costly and
laborious process, hindering its use as a routine biomedical
tool. Recent times are seeing rapid developments in this field,
both in the availability of novel sequencing platforms, as
well as supporting technologies involved in processes such
as targeting and data analysis. This is leading to significant
reductions in the cost of sequencing a human genome and the
potential for its use as a routine biomedical tool. This review
is a snapshot of this rapidly moving field examining the
current state of the art, forthcoming developments and some
of the issues still to be resolved prior to the use of new
sequencing technologies in routine clinical diagnosis.
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Introduction
The basic principles of DNA sequencing have remained
constant since the development of the first practical method
by Sanger et al. (1977). Even so, the classic Sanger method
has undergone various modifications and refinements in the
intervening years, most recently driven by the requirements
of the Human Genome Project to facilitate automation and to
increase throughput. Perhaps most significantly, contempo-
rary methods use four different base-specific fluorescent dyes
(Smith et al. 1986) instead of radioactive labels, and cum-
bersome gel electrophoresis has been replaced by automated
capillary electrophoresis (Luckey et al. 1990). These devel-
opments have dramatically increased the efficiency of San-
ger sequencing, which is now widely considered the gold
standard for clinical diagnostic use. However, the technique
remains too laborious and expensive for routine sequencing
of anything more than a few genes. In an attempt to address
this short-coming, a diverse array of new sequencing tech-
nologies have been developed and are currently in develop-
ment. Although the widely perceived aim of practical and
affordable whole genome sequencing is ambitious, requiring
major improvements in run capacity, speed of processing and
cost, progress to date has been remarkable (see reviews
Mardis 2011; Metzker 2010; Pettersson et al. 2009; Tucker
et al. 2009; Voelkerding et al. 2009).
Classification of technologies
The terminology surrounding the new sequencing tech-
nologies is diverse and often confusing with terms such
as ‘next generation’, ‘massively parallel’ and ‘clonal’
sequencing being used as global classifiers for, what is,
essentially the same thing. In an attempt to bring some
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clarity to classification we have divided DNA sequencing
technologies into three generations (Pettersson et al. 2009).
The first generation is synonymous with Sanger
sequencing, which has been predominant since the 1970s.
The defining characteristics of this technology are that each
sequencing reaction represents a single, predefined target (up
to about 1 kb) and this represents all copies of that target
present in the original sample and thus its allelic content. The
underlying principle of all post-Sanger DNA sequencing
technologies, which is enabling the explosion in capacity and
exponentially decreasing costs, is massive parallelisation.
A fragmented input sample is captured on an array in such a
way that each spatially identifiable location or feature is
populated by a single target molecule. Depending on the
technology a single sequencing array may comprise many
millions or even billions of features, which are all sequenced
in parallel in a single run, each feature generating a single
sequencing ‘read’. This is fundamentally different from
Sanger sequencing in two key respects: first, the specific
location of the reads is not pre-determined and so must be
computationally determined (referred to as mapping or
alignment); and second, because each read represents a
single starting molecule, multiple coverage is required to
analyse the full allelic content of the sample.
With second generation sequencing, widely referred to as
‘next generation sequencing (NGS)’ it is necessary to clonally
amplify the isolated targets in order to generate sufficient signal
for detection during the sequencing run. This process is usually
performed in situ on a solid substrate and generates clusters of
many thousands of identical DNA targets (sometimes called
polonies) at each feature. With these technologies sequencing
is performed through stepwise incorporation of suitably mod-
ified subunits. Generally speaking read lengths are shorter than
thoseachieved by Sanger sequencing, although theyare rapidly
improving. This is an important consideration since short read
length can make accurate assembly and alignment computa-
tionally challenging (Flicek et al. 2011; Li et al. 2008; Li and
Durbin 2009). The key difference with third generation, or
‘next next generation’, sequencing is that the chemistry and/or
detection has been refined so that no clonal amplification of the
target is required before the run. These technologies are
predominantly still in development and use a wide range of
different detection methodologies.
Below we review the principles behind these alternative
technologies, compare and contrast their characteristics, and
provide an overview of some of the targeting techniques and
bioinformatics tools that have been developed alongside them.
Second generation sequencing
Since late 2004, three principal NGS technologies
have been commercially available (see Table 1). These
technologies have been made available on an increasing
range of platforms designed to suit different applications
and capacity requirements from large genome centres
down to the clinical laboratory. The underlying chemistries
are briefly described below.
Reversible termination
This method closely resembles the Sanger sequencing-by-
synthesis method, but uses special fluorescently labelled
terminator nucleotides, which allow the chain termination
process to be reversed (Bentley et al. 2008). It was origi-
nally developed by Solexa and is now commercialised by
Illumina through the Genome Analyser and HiSeq systems;
a further addition to the range will be the MiSeq, a lower
capacity instrument due for release in mid-2011.
Template DNA molecules are generated by fragmenta-
tion of the sample followed by ligation of end specific
universal adaptors. These fragments are then hybridised to
a dense ‘lawn’ of universal probes immobilised to a glass
surface known as a flow cell upon which both amplification
and sequencing take place. Clonal amplification is per-
formed using a process termed ‘bridge amplification’; a
surface PCR which uses two tethered universal primers to
create dense clusters of identical DNA across the plate. The
sequencing reaction begins with the addition of a universal
sequencing primer, which hybridises to the adaptor
sequences added in the first stage. The sequencing chem-
istry involves three stages. First, chain extension is per-
formed using DNA polymerase and the four reversible
nucleotide terminators, each labelled with a different
fluorescent dye. Incorporation of a complementary nucle-
otide results in termination of polymerisation—this process
is allowed to run to completion to ensure all templates on
the flow cell are extended by a single base. Next, unin-
corporated nucleotides are washed off and the incorporated
base on each cluster is identified by colour imaging.
Finally, the dye and the terminating group are chemically
cleaved to prepare the templates for the next round of
incorporation and imaging. These three stages are repeated
over several hundred cycles generating a temporal series of
colour images, which can be computationally converted
into sequence reads each corresponding to a feature on the
array.
Pyrosequencing
Pyrosequencing is also based on a sequencing-by-synthesis
technique, but rather than measuring fluorescence associ-
ated with specific nucleotides, it relies on indirect detection
of incorporation events (Margulies et al. 2005). This
technology was available in individual reaction form
(Qiagen) before a massively parallelised version was
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commercialised by Roche/454. Two platforms supporting
this chemistry are now available: the Genome Sequencer
FLX and the GS Junior, a low capacity version.
Template DNA molecules can be generated either by
fragmentation or standard PCR. If fragmentation is used,
universal adaptors are ligated to the fragment end, similar
to the method used by Illumina. In the case of PCR, the
adaptors can be built into the primers. The prepared frag-
ments are hybridised to special beads upon which both
amplification and sequencing takes place; the beads are
used in excess to ensure that each bead binds a maximum
of one template molecule. A mix of these beads, PCR
reagents and oil is then agitated to form an emulsion of tiny
oil reaction chambers, each containing a single bead with a
single molecule attached and all the components of a PCR.
This is subjected to thermal cycling to clonally amplify
the DNA template on the surface of each bead (known as
emulsion PCR or emPCR). The sequencing reaction is
performed on a specially fabricated ‘PicoTitre Plate
(PTP)’—this comprises millions of microscopic wells,
each just big enough to contain a single template bead.
After breaking the emulsion the beads are loaded onto the
PTP along with other, much smaller beads that contain all
the reagents necessary for the sequencing reaction except
the nucleotides. Sequencing proceeds with the sequential
addition of each individual nucleotide in turn (i.e. A, then
C, then G, then T). If a nucleotide is incorporated by DNA
polymerase into the growing DNA strand, an inorganic
phosphate ion is released. This initiates an enzyme cascade
resulting in the release of a flash of light. Since no termi-
nators are used in this chemistry, incorporation of nucle-
otides into homopolymer stretches continues until a
different base is encountered and the associated light flash
is proportionally brighter. The location and intensity of
light emitted is detected by a camera across the whole
plate. Excess nucleotides are then washed off in prepara-
tion for the next cycle. This process is repeated several
hundred times to build the temporal image sequence.
Unlike other chemistries the number of incorporation
cycles required to reach a particular read length is depen-
dent on the sequence composition of the template. On
average read length is expected to be *2.59 cycle number
but this could be less with more homopolymers. As before
the temporal series of images can be computationally
converted into sequence reads.
Sequencing by ligation
Unlike the previous techniques, this method does not
involve polymerase based DNA synthesis, but instead uses
ligation of fluorescently labelled hybridisation probes
to determine the sequence of a template DNA strand two
Table 1 Summary of existing
NGS platforms
Platform Illumina/Solexa
GAIIe, GAIIx, HiSeq 
1000, HiSeq 2000, 
MiSeq
Roche/454
GS FLX, GS Junior
Life Technologies/ 
Applied Biosystems 




Pyrosequencing Sequencing by 
Ligation
Loading Adaptors on template 
DNA bind high density 
primers across surface of 
slide
Adaptors on template 
DNA bind primers on 
beads, one molecule per 
bead
Adaptors on template 
DNA bind primers on 




Surface PCR used to 
generate clusters by 
bridge amplification
Emulsion PCR used to 
create clusters on beads
Emulsion PCR used to 
create clusters on beads
Parallelisation Random array on flow 
cell
Beads loaded onto high 
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Beads immobilised on 
high density glass slide
Sequencing 
enzyme
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bases at a time (Shendure et al. 2005). It has been com-
mercialised by Life Technologies/Applied Biosystems
through the SOLiD (Sequencing by Oligonucleotide
Ligation and Detection) system.1
Template DNA molecules are prepared by fragmenta-
tion, adaptor ligation, hybridisation to beads and emPCR
in a similar fashion to that described for the Roche/454
system above. After breaking the emulsion the beads are
immobilised at high density on a glass slide. Sequencing
proceeds with the addition of a universal primer, followed
by fluorescently labelled oligonucleotide probes. Each
probe comprises eight bases, of which only the first two
define the probe whilst the following six are degenerate
(i.e. able to pair with any nucleotide sequence on the
template strand). After the complementary probe hybri-
dises to the template DNA, it is chemically linked to the
growing strand by the enzyme DNA ligase. The flow cell is
then washed to remove excess probes and imaged to record
the ligation cycle. Then, the three terminal degenerate
bases, along with the fluorescent dye, are cleaved from
the bound probes and the flow cell is washed again (this is
known as a ligation cycle). This process is repeated a
number of times, after which the newly synthesised strand
is entirely denatured and removed from the template. At
this point a new primer, which is one base shorter than that
previously used (i.e. n - 1), is hybridised to the template
and a new round of ligation cycles performed. In all, five
rounds of ligation cycles are performed, each one using a
primer one base shorter than the last. By this process, all
bases on the template strand are interrogated twice.
Counter-intuitively, although there are 16 possible per-
mutations of the first two bases in the probe, only four
coloured dyes are used; thus each colour represents four
possible different two-base permutations. The arrangement
of colours is such that if the first base is known, the second
can be inferred. Since the first base in the sequence belongs
to the universal primer added initially, the rest of the
sequence can be sequentially inferred from the raw colour
data, which is called colour space, by applying logical
rules. This system, known as 2-base encoding, enables
miss-called bases to be distinguished from true sequence
variants as the former lead to logical impossibilities.
Third generation sequencing
A large number of companies are involved in developing
much faster and higher throughput third or next–next
generation DNA sequencing systems, some of which have
already launched and some of which are still in stealth
mode. Most of these are focussed on sequencing single
molecules of DNA in real-time, and although many are
based on sequencing-by-synthesis, there are several novel
methodologies such as monitoring the passage of DNA
through nanopores. A key advantage of single molecule
sequencing is that no clonal amplification is required. This
not only reduces preparation time, but effectively elimi-
nates biases and errors introduced at this stage. In addition
it is generally expected that these methods will generate
much longer reads (potentially tens to hundreds of kilo-
bases) which will enable much more accurate mapping,
particularly in repetitive regions, and facilitate haplotyping.
Moreover, some technologies have been demonstrated to
be capable of distinguishing methylated cytosine bases,
which could open the door to direct epigenetic analysis.
There are numerous third generation sequencing plat-
forms at very different stages of development—ranging
from basic research through to a launched product—which
may be destined for different applications based on the
precise idiosyncrasies of the sequencing chemistry and
resultant performance metrics (e.g. error rate, read length,
yield per run, cost per base, etc.—see later). The third
generation technologies can be divided into categories
based on the method they use to detect the DNA sequence:
Fluorescence
Most of the third generation sequencing platforms under
development using fluorescence detection are based on the
standard sequencing-by-synthesis method. The first single
molecule sequencing platform to market was the Heliscope
from Helicos Bioscience (Harris et al. 2008), launched in
2009, which is based on a similar methodology to that
described for the Solexa/Illumina second generation plat-
form. However this is a single molecule method and all the
nucleotides have the same fluorescent label which acts as
the terminating moiety. This means that the nucleotides
need to be added individually and sequentially in order to
identify which base is added when (Bowers et al. 2009).
Following washing of excess nucleotides and polymerase,
the slide is imaged to identify where bases were incorpo-
rated. The dye is then cleaved in preparation for the next
nucleotide addition and the process repeated for each
nucleotide, with each cycle extending the DNA strand by a
single base. The data are then analysed to build up a
sequence read for each location.
Another single molecule approach is the SMRTTM
chemistry which has been made commercially available on
the PACBIO RS platform from Pacific Biosciences. One of
the main problems with single molecule sequencing is that
the incorporation event that needs to be detected is so small
1 An open platform based on sequencing-by-ligation has also been
developed by George Church/Dover Systems, known as the Polonator
(Shendure et al. 2005), but is not described further as it had a
substantially smaller impact than the other technologies.
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it is difficult to detect above background noise. This is the
main reason for the use of clonal amplification in second
generation systems. Pacific Biosciences have solved this
problem by performing the sequencing in specially
designed wells called zero mode wave guides which
effectively eliminate the background noise (Eid et al. 2009).
Template DNA forms a complex with the polymerase
and nucleotide incorporation is detected by laser excitation
and fluorescence monitoring in each well. The difference
between this method and others that use fluorophores is that
the dye is attached to the phosphate of the nucleotide rather
than the base itself. Thus it is cleaved and released as a
natural part of DNA synthesis, resulting in release of the
dye without interruption to the sequencing process. The
sequencing is therefore both single molecule and real-time.
Life Technologies have developed an approach which
uses a DNA polymerase modified by the addition a quan-
tum dot [Qdot (Karow 2010b)]. This is a tiny nanocrystal
that absorbs photons of light, then re-emits photons at a
different wavelength. Template DNA is immobilised to the
surface of a glass slide, and sequencing is initiated by the
addition of a primer, the modified DNA polymerase and
nucleotides with base specific fluorescent labels. As bases
are incorporated the nucleotide labels are energised by the
Qdot on the polymerase in a process known as fluorescence
resonance energy transfer (FRET), which generates a very
strong localised fluorescence signal (around 100-fold
greater than standard dyes). FRET can only occur when the
two fluorescent moieties (polymerase and nucleotide) are
in close proximity to each other i.e. at incorporation thus
elegantly eliminating interfering background fluorescence
in the reaction chamber. At the end of a sequencing run
both the polymerase and newly synthesised DNA strand
can be removed, allowing the immobilised template DNA
to be sequenced repeatedly. Life technologies claim that
this system allows the read length and sequencing accuracy
to be tailored to the application by adjusting the mode of
repetitive sequencing.
There are also numerous other smaller companies devel-
oping third generation DNA sequencing platforms based on
fluorescence detection, such as GnuBio, which is developing
a microfluidics device that uses microdroplets as miniature
reaction vessels, thus vastly reducing the cost of the reagents.
Electronic
Various third generation DNA sequencing platforms are
being developed that are capable of converting a DNA
sequence directly into an electrical signal. This essentially
amounts to direct generation of digital information prom-
ising the enticing prospect of label-free sequencing. Plat-
forms using such technology would be extremely cheap to
produce and be both fast and scalable.
The system recently released by Ion Torrent/Life
Technologies uses a sequencing-by-synthesis method
almost identical to pyrosequencing. The key difference is
that incorporations are detected by monitoring the release
of H? ions (protons) which are also released as a by-
product of nucleotide incorporation (Karow 2010a). A
proprietary semi-conductor chip, which is essentially a
miniature pH meter, is divided into wells in which the
sequencing reactions take place. If a nucleotide is incor-
porated in a particular well, a single H? is release into
solution and a concomitant change in acidity (pH) is
detected as a voltage shift by sensors. The magnitude of the
pH change can be related to the number of molecules of
a particular base incorporated. Currently this system does
not detect single molecules and amplification is required
prior to sequencing, but the synthesis reaction is detected in
real-time and no modified reagents are required.
A majority of other platforms currently under develop-
ment for using electronic detection are not based on the
sequencing-by-synthesis method, but on an entirely new
method using either biological or solid state nanopores.
These technologies monitor changes in electrical current as
DNA strands or individual bases pass through a nanopore.
The sequencing chamber is divided into two sub-chambers
by a synthetic membrane or some other septa. Each
sequencing chamber contains a single nanopore penetrating
the septum providing a single channel between the two
chambers. The nanopores themselves can either be small
holes in an inorganic membrane (solid-state nanopores),
such as silicon nitride (Aksimentiev et al. 2004) or
grapheme (Garaj et al. 2010), or modified natural channel
proteins like a-haemolysin (Howorka et al. 2001; Olasag-
asti et al. 2010) embedded in a lipid bilayer or synthetic
membrane. Nanopore sequencing technologies are based
on one of two approaches—either the DNA strand itself
passes through the nanopore (strand sequencing), or indi-
vidual bases are cleaved from the target DNA and fed
sequentially through the nanopore. A voltage is placed
across the membrane to drive the translocation of nega-
tively charged DNA molecules through the pore. As DNA
bases pass through the pore, the current is blocked and
since each base blocks the current by a different amount the
strand composition can be determined.
Numerous companies are currently developing nano-
pore-based DNA sequencing platforms, including Oxford
Nanopore Technologies, NABSys, base4innovation, and
IBM/Roche. Whilst this technique is extremely promising,
there are still challenges to be overcome both technical,
such as controlling the passage of bases though the nano-
pore to allow sequencing of consecutive bases, and those
related to system performance, such as pore shelf life and
parallelisation (Branton et al. 2008; Kircher and Kelso
2010). Perhaps the most advanced to date is the platform
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under development by Oxford Nanopore Technologies,
which uses a-haemolysin nanopores modified with a
cyclodextrin ring covalently bound in the barrel. The DNA
is digested by an exonuclease and the individual bases are
drawn through the pore one at a time driven by an electrical
potential (Astier et al. 2006; Wu et al. 2007). It has been
demonstrated that this system can also distinguish 5-methyl
cytosine thus enabling direct methylation analysis (Clarke
et al. 2009).
Recently an alternative method for detection and iden-
tification of nucleotides has been described: here the
transverse conductivity of the molecule is measured as it
passes between two electrodes embedded in a solid state
nanopore (Tsutsui et al. 2010, 2011). The authors suggest
alternative methods for translocation of the DNA through
the nanopore such as ‘magnetic tweezers’ (Peng and Ling
2009).
Atomic
Another novel technique for DNA uses transmission elec-
tron microscopy to directly visualise strands of DNA that
have been suitably modified with heavy metal atoms to
distinguish the bases (Krivanek et al. 2010). This method is
being developed and commercialised by several compa-
nies, including Halcyon Molecular and ZSGenetics. The
use of scanning tunnelling microscopy to sequence DNA
molecules has also been described (Tanaka and Kawai
2009).
Targeting methods
Although NGS platforms have massively increased
throughput, sequencing the entire genome is still neither
practical nor affordable for most clinical applications.
Moreover whole genome sequencing may not be desirable
in a medical setting for reasons of interpretation and
reporting. Consequently, many studies employ new
sequencing technologies for targeted sequencing of specific
regions of interest as opposed to whole genomes. This
ranges from the analysis of gene families or large regions
that are associated with a specific disease or pharmacoge-
netic effects, to the analysis of all coding exons in the
genome (the ‘exome’) (Teer and Mullikin 2010; Majewski
et al. 2011). Since NGS platforms sequence the entire input
sample, it is necessary to have a method of selecting the
desired DNA before sequencing. There are a three general
approaches to targeting (Summerer 2009; ten Bosch and
Grody 2008)—PCR-based methods, circularisation meth-
ods and hybridisation capture. The relative advantages and
disadvantages of these approaches are contrasted in
Table 2.
The current method of targeting for capillary sequencing
is the polymerase chain reaction (PCR) (Saiki et al. 1985).
This can equally be used for preparation of targets for NGS
but owing to the massive capacity of these platforms very
large numbers of PCRs are required to fill a run. The
processing required can be limited by utilising multiplex
PCR or long range PCR (Fredriksson et al. 2007; Varley
and Mitra 2008). Commercial solutions to this problem
include the RainStorm technology from RainDance Tech-
nologies which uses an emPCR approach to simultaneously
amplify up to 4,000 short DNA sequences in separate
microdroplets (Tewhey et al. 2009), and the Access Array
from Fluidigm which uses proprietary microfluidics to
setup an array of 2,304 PCRs (48 samples 9 48 assays). It
should be noted that neither of these systems is actually
multiplex as the individual reactions are separated—this
enables much higher levels of parallelisation than are
achievable in a single reaction.
Circularisation methods are designed to resolve the
interference issues that limit the level of multiplexing
achievable by standard PCR and are suitable for targeting
small to medium sized regions of interest. Several
approaches have been demonstrated including gene col-
lector (Fredriksson et al. 2007) gene selector (Dahl et al.
2005, 2007) and connector inversion probes (Akhras et al.
2007) but all are essentially based on padlock and molec-
ular inversion probes (Krishnakumar et al. 2008; Li et al.
2009). The basic principle is that large panels of target
molecules can be selected and circularised in a single
reaction using specially designed probes containing uni-
versal sequences. The reaction is then subjected to
Table 2 Advantages and disadvantages of different chemical targeting approaches
Method Advantages Disadvantages
PCR High sensitivity, specificity, reproducibility and uniformity High cost, low throughput, and cannot be used for large
regions or a very large number of genes
Circularisation Low cost (if many samples), easy to use, high sensitivity
and specificity
Uniformity and sensitivity depends on design of probes.
Cannot be used for a very large number of genes
Hybrid
capture
Medium cost, easy to use, high sensitivity and specificity. Can
target large sections of DNA and large numbers of genes
Uniformity and sensitivity depends on design of probes.
Array design may be rather inflexible
Source: Mamanova et al. (2010)
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exonuclease digestion which degrades all the unwanted
DNA but leaves the targets untouched since, being circles,
they have no ends. The target sequences can then be
amplified using the universal sequences to generate suit-
able target material for sequencing.
The final method of targeting is hybridisation, which is
based on the same principle as DNA microarray technol-
ogy. Oligonucleotide probes are used to pull-down
sequences of interest from whole, fragmented genomic
DNA. Unwanted DNA is then washed off, and the captured
material eluted and prepared for sequencing. The capture
capacity ranges from a few Mb up to the entire exome
(Hodges et al. 2007; Porreca et al. 2007) using two general
methodologies: conventional solid state arrays (on-array
capture) and paramagnetic beads (in-solution capture)
(Albert et al. 2007; Chou et al. 2010; Gnirke et al. 2009). A
number of custom hybridisation platforms are available
including Agilent, Roche Nimblegen and Illumina.
The method of choice is dependent on application; in
particular target size, type of target and sample number,
required performance, ease of use and costs (Albert et al.
2007; Mamanova et al. 2010). Ideally the targeting method
should allow enrichment of multiple different loci inde-
pendent of their size, sequence composition or spatial
distribution, and should be amenable to automation so that
it can match the sequencing capacity. However, the current
approaches have their own biases (see Table 2), which
relate both to the types of sequences that they are able to
capture and their ease of use. Key issues, which apply to all
methods with varying degrees are uniformity, efficiency of
coverage and off-target capture. Whilst these methods are
continually being improved, it may ultimately be more
cost-effective to sequence a whole genome, computation-
ally masking regions of the genome that are irrelevant to a
particular clinical question, and target analysis only to
regions with proven clinical significance.
Performance metrics
Rather than review the current performance of each plat-
form (which can be found on each of the manufacturer’s
websites and at http://www.molecularecologist.com/next-
gen-fieldguide/), we outline some of the factors that affect
performance and influence the utility of all whole genome
sequencing technologies.
Analytical accuracy, systematic errors and quality
of base calls
In addition to amplification errors (which will be elimi-
nated by single molecule sequencing), all sequencing
methodologies suffer from both random and systematic
errors. The raw accuracy of the sequencing process and
quality of base calling are critically important factors,
particularly for clinical diagnostics. A quality score rep-
resenting of the probability that the base is called correctly
is assigned to each base (These are generally given on a
logarithmic scale so that Q10 would be 10% probability
of miscall Q20 is 1% probability, Q30 is 0.1% probability
etc). Factors affecting the quality score include signal
intensity, background noise in the reaction itself or gen-
erated by the instrument and crosstalk between clusters.
Errors can include overcalls and undercalls (insertions or
deletions of bases from the sequence) as well as miscalls
(incorrect base assigned) (Albert et al. 2007; Brockman
et al. 2008). Different sequencing technologies are prone to
different systematic errors, which influence their utility for
different applications; for example, accurately sequencing
homopolymeric regions can be difficult using pyrose-
quencing due to intermediate fluorescence signal intensities
resulting from the incorporation of n identical nucleotides.
Sanger sequencing has a low (but non-zero) error rate
of around 10-4 to 10-5 for single calls (one error per
1,000–10,000 bases), but the accuracy for detecting het-
erozygous variants is much more difficult to assess and is
almost certainly context dependent to some extent. When it
comes to detection of a low level variant, for example
mosaic or somatic mutation, the limit of detection in terms
of minor allele representation is only around 20% for Sanger
sequencing. Current NGS platforms have a somewhat
higher raw error rate of around 10-2 to 10-3 (depending on
read length), but this is easily offset by increasing read depth
(i.e. consensus accuracy). In fact the desired accuracy can
essentially be determined by altering the read depth
appropriately. In contrast to Sanger sequencing detection of
low level variants is basically limited by the raw error rate
and would be substantially below 0.1%.
Read depth, genome coverage and uniformity
The read depth or depth of coverage refers simply to the
number of times a base is sequenced in a single run of the
machine. The required read depth varies depending upon
the specific application and level of certainty required for
the result. However, coverage of the genome is non-uni-
form due to factors such as repetitive elements, non-uni-
form targeting and variable GC content, which affects both
amplification and sequencing efficiency (Dohm et al.
2008). For diagnostic purposes it is necessary to increase
overall coverage to ensure the regions with least coverage
meet the desired standard; any that do not should be failed.
This can be very costly in terms of capacity, particularly
where coverage is very variable. The theoretical depth
required to detect a heterozygous variation with particular
probability of success can be calculated. For re-sequencing
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applications mapping the reads is guided by a reference
sequence and theoretically requires much lower coverage
(8–12x), than assembling genomes de novo (25–70x)
(Schuster 2008). However, in practice, a depth of coverage
of around 209 at each base is required for confident variant
calling (Bentley et al. 2008).
Read length (number of bases per read)
Read length is an important factor in certain applications,
such as sequencing through repetitive regions, identifying
genomic rearrangements and getting short range haplotype
information. In addition, longer reads make alignment to a
reference sequence substantially easier by reducing the
number of potential matches. Current second generation
NGS platforms achieve reads length of 35–400 bases
(Metzker 2010; ten Bosch and Grody 2008), but this is
rapidly improving. It is anticipated that many the third
generation platforms will have substantially longer read
lengths. For example Oxford Nanopore Technologies,
Pacific Biosciences and Life Technologies claim that their
new platforms will have read lengths in excess of 1 kb and
claims beyond this are not infrequent.
Sample multiplexing
Factors such as run capacity, sample multiplexing, run time
and cost all have a major impact on the suitability of a
particular platform for a particular application or labora-
tory. These factors vary substantially between machines,
applications and chosen sequencing protocol. Whilst NGS
has significantly reduced the per-base cost of sequencing,
cost per test savings will only be realised if the capacity of
the instrument is effectively used. In many cases the format
of the experiment does not require the full capacity of a run
for a single sample so methods for analysing multiple
samples in a single run are important. Several methods are
available to achieve such sample multiplexing (ten Bosch
and Grody 2008). For targeted sequencing, it is possible to
mix multiple different tests so that results from each spe-
cific test relate to only one individual patient. However,
this is only effective if the reads are mapped to specific
regions of interest and in many cases it is preferable to use
the whole genome as a reference as this guards against non-
specific targeting. In addition, many sequencing platforms
allow physical separation between samples, for example by
dividing the flow cell in to a number of channels. Finally,
DNA ‘barcode tags’ can be added to the ends of DNA
fragments during initial preparation. These are sequenced
along with the fragment during the run and serve to identify
the source of each sequence read during analysis (Binladen
et al. 2007; Meyer et al. 2007).
Reagent and instrument cost
Reagent cost for sequencing has plummeted over the last
decade, from a cost of around $500/Mb for Sanger
sequencing reagents, to less than $0.50/Mb for reagents on
the newest NGS platforms (Wetterstrand 2011). However,
the sequencing machines themselves are often fairly
expensive ranging from US$ 0.2–1 million. With ever
increasing capacity the output from sequencing runs
becomes greater and greater. The cost of handling and
storing all this data should not be treated lightly—ulti-
mately this is likely to be a more significant cost than
generating the data.
Data analysis and interpretation
Massively parallel sequencing generates an enormous
volume of data, the analysis of which requires substantial
computational power, purpose-built bioinformatics tools
and accurate databases of genomic variation to aid inter-
pretation. The informatics pipeline for human genome
resequencing using NGS technology can broadly be divi-
ded into three analytical steps:
1. Primary analysis: base calling—converting light sig-
nal intensities into a sequence of nucleotides. This is
generally performed automatically by software on the
sequencing machine itself and each call is associated
with a raw quality score.
2. Secondary analysis: alignment and variant calling—
mapping DNA reads to an annotated reference
sequence and determining the extent of variation from
the reference.2 Because it is often not possible to
unambiguously align a read to a unique position in the
reference genome, particularly allowing for variation
between the reference and the sample genome, a
mapping quality score may be used to measure the
likelihood that a read is mapped correctly. Numerous
algorithms and software packages have been devel-
oped for this process (Flicek and Birney 2009; Magi
et al. 2010) which is becoming increasingly automated.
Various dedicated software packages have also been
developed specifically for cancer genome assembly
and variant calling, which take into account factors
such as genetic heterogeneity in the sample (Ding et al.
2010; Magi et al. 2010). In the final stage of the
alignment phase, sequence data are annotated with
2 The process of alignment is substantially harder for de novo
genome assembly, as there is no reference sequence against which
DNA reads can be compared and mapped. Therefore specialist
genome assembly methodologies and software have been developed,
which are no longer directly relevant to human genome sequencing.
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structural and functional biological information and
visualised through a graphical interface or genome
browser.
3. Tertiary analysis: interpretation—analysing and filter-
ing variants to assess their inheritance, uniqueness, and
likely functional impact (Kuhlenbn˜umer et al. 2010).
This process requires comparison against databases of
genomic variation (Kuntzer et al. 2010) (including
both normal and pathogenic variants) and algorithms
for evaluating the likely pathogenicity of a particular
mutation [e.g. by assessing haploinsufficiency (Huang
et al. 2010) of large deletions or loss of function
variants (MacArthur and Tyler-Smith 2010), predict-
ing the effect of amino acid substitutions caused by
non-synonymous coding variants (Ng and Henikoff
2006)]. Although many software packages already
exist for this process, accurate interpretation of the
effect of genomic variants in an individual is still in its
infancy, and more purpose-build packages will need to
be developed to allow clinical diagnostic use. Mean-
ingful clinical interpretation is likely to remain a major
challenge for the foreseeable future.
A vast array of software packages are now available,
both commercial and open source (i.e. freely available).
Whilst open source options may offer a more flexible final
solution, building a pipeline involves linking multiple
software units, each performing a specific task, and
remains the domain of dedicated bioinformaticians. The
scope and applicability of integrated commercial packages
is now enabling laboratory scientists to directly analyse
their own data although it should be noted that significant
time and effort will be necessary in order to acquire an
appropriate level of understanding of the processes and
how they affect the final results. A useful reference for
available packages can be found at: http://seqanswers.com/
forums/showthread.php?t=43.
Service providers
A number of national and international centres offer both
data production and analysis services. In the UK the MRC
has funded the establishment of four regional sequencing
hubs which are primarily intended to support small and
medium sized research projects, and the Wellcome Trust
Sanger Institute continues to undertake large-scale
sequencing research projects. In addition to research
facilities in numerous countries international providers
include Complete Genomics, a US company established in
2005 with the specific aim of providing a comprehensive
human DNA service for pharmaceutical and academic
research, and BGI (formally Beijing Genomics Institute),
the first citizen-managed, non-profit research institution in
China with probably the largest sequencing capacity in the
world. It is unclear what effect these integrated service
providers will have on the future of human whole genome
sequencing, and currently most research and diagnostic
laboratories both produce and analyse their own data.
Conclusion
The era of affordable genome resequencing is almost upon
us, opening opportunities for both research and medical
diagnostics. Exciting clinical applications of NGS and
human genomes include
• Multi-gene diagnostic panels (Morgan et al. 2010)
• Achieving a molecular diagnosis for rare genetic
diseases (Lupski et al. 2010; Ng et al. 2010a, b;
Worthey et al. 2011; Vissers et al. 2010)
• Tissue matching and HLA-typing (Bentley et al. 2009;
Gabriel et al. 2009; Lind et al. 2010)
• Non-invasive prenatal diagnosis (Chiu et al. 2008; Fan
et al. 2008; Lo et al. 2010)
• Quantifying the burden of disease from solid tumours
(Leary et al. 2010; McBride et al. 2010) and
• Cancer genome profiling leading to stratified treatment
regimens (Campbell et al. 2010; Diamandis et al. 2010;
Stratton et al. 2009)
RNA sequencing (RNA-seq) and chromatin immunopre-
cipitation (ChIP) sequencing can also be used to study gene
expression and for detection of somatic mutations, gene
fusions, and other non-mutational events, an understanding
of which can have an impact on management of diseases
such as cancer (Cowin et al. 2010; Robison 2010).
However, numerous barriers to clinical translation still
exist, including: validation of the technology; standardi-
sation of the analysis pipeline; integration of information
from the numerous databases of genomic variation; build-
ing a robust evidence base to allow clinical interpretation
of novel variants; developing a service delivery infra-
structure that can capitalise upon the high-throughput
advantages of new sequencing technologies; providing an
appropriately skilled health care workforce to deal with
genomic medicine; and addressing the numerous ethical,
legal and social implications of sequencing, storing and
accessing whole genomes. These issues will need to be
addressed before human whole genome resequencing can
be used routinely in the clinic.
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